sm14 vaccine
Vaccineexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2011 (NCT01154049)
Timeline
Indications
Mechanism of action
- Schistosoma mansoniImmunity, active
Schistosoma mansoni immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- sm14 vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05658614 | Phase 2 | Jul 1, 2022 | Biomedical Research Center EPLS, Oswaldo Cruz Foundation |
| NCT03799510 | Phase 2 | Dec 13, 2018 | Biomedical Research Center EPLS, Biomedical Research Center ESPOIR POUR LA SANTE, Immune Design, Orygen Biotecnologia SA, Oswaldo Cruz Foundation |
| NCT03041766 | Phase 2 | Dec 6, 2016 | Biomedical Research Center EPLS, Biomedical Research Center ESPOIR POUR LA SANTE, Immune Design, Orygen Biotecnologia SA, Oswaldo Cruz Foundation |
| NCT01154049 | Phase 1 | Mar 1, 2011 | Government of Brazil, Oswaldo Cruz Foundation |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Oswaldo Cruz Foundation | Academic/Hospital | 4 | 4 | 2 | 2011 |
| Biomedical Research Center EPLS | Academic/Hospital | 3 | 0 | 1 | 2016 |
| Biomedical Research Center ESPOIR POUR LA SANTE | Academic/Hospital | 2 | 0 | 1 | 2016 |
| Immune Design | For profit | 2 | 0 | 1 | 2016 |
| Orygen Biotecnologia SA | For profit | 2 | 0 | 1 | 2016 |
| Government of Brazil | Government | 1 | 0 | 1 | 2011 |
6 organizations
Page 1 / 1